A pre-market check on Monday showed Exicure Inc. (XCUR) advancing 42.96 percent at $1.93. XCUR stock lost -0.74% to close at $1.35 during the last trading session. There was a price range of $1.34 to $1.40 for XCUR stock. Trading volume of XCUR stock was 0.11 million shares, which was below its 100-day average of 0.48 million shares. Since the beginning of the month, XCUR stock has lost -10.00%, a decrease of -5.59% in the previous five days. As a result of collaboration with a neurosciences firm, XCUR stock is skyrocketing.
What is XCUR Stock collaborating on?
Exicure is a clinical-stage biotechnology company developing therapies for neurological diseases, Immuno-oncology, inflammatory diseases, and other genetic disorders. XCUR’s proprietary DNA technology allows it to mimic the genetic makeup of the human body. A proprietary SNA architecture developed by XCUR may offer advantages over other nucleic acid therapies in terms of its chemical and biological properties, and it may have therapeutic potential to address diseases not typically addressed by other nucleic acid therapies.
As part of its preclinical development, XCUR is looking to develop XCUR-FXN, an intrathecal treatment for Friedreich’s ataxia (FA) that uses lipid-nanoparticle-based SNAs. XCUR is conducting Phase 1b/2 clinical trials with its therapeutic candidate cavrotolimod (AST-008). Cambridge, Massachusetts, and Chicago, IL, are XCUR’s base of operations.
Exicure and Ipsen (Euronext: IPN; ADR: IPSEY) have formed an exclusive collaboration to develop and commercialize spherical nucleic acids (SNAs) as potential treatments for Huntington’s disease and Angelman syndrome.
- Bringing together XCUR’s expertise and Ipsen’s strong neuroscience heritage, the collaboration represents an important step in maximizing the potential from this new technology.
- It is a milestone in XCUR’s commitment to people around the world living with neurodegenerative conditions.
- The agreement gives Ipsen exclusive rights to license SNA-based therapeutics resulting from two collaboration programs for Huntington’s disease and Angelman syndrome.
- XCUR will receive $20 million from Ipsen as an upfront payment and will be responsible for certain preclinical activities.
- It is anticipated that Ipsen will exercise its option to further develop and commercialize the licensed products.
- In the case of Ipsen opting into both programs, XCUR will receive a $20m upfront payment, as well as a $20m option exercise fee, milestone payments, and tiered royalties.
How will XCUR leverage this opportunity?
As part of its collaboration with Ipsen, Exicure (XCUR) will also be able to apply its technology to diseases such as Huntington’s disease and Angelman syndrome, which require deep brain penetration and technological advances to target previously inaccessible targets. XCUR views its platform technology as a solution to the challenges related to first-generation oligonucleotides and a means to deliver new medicines to patients.
